Duvortuxizumab

From WikiMD.org
Jump to navigation Jump to search

Duvortuxizumab

Duvortuxizumab (pronunciation: du-vor-tux-iz-u-mab) is a monoclonal antibody designed for the treatment of cancer. It is currently under investigation in clinical trials for its potential use in various types of cancer, including leukemia and lymphoma.

Etymology

The name "Duvortuxizumab" is derived from the International Nonproprietary Names (INN), where "zu" denotes humanized antibody, "tuxi" refers to the targeted antigen (CD19 in this case), and "mab" is the suffix for monoclonal antibodies.

Mechanism of Action

Duvortuxizumab works by binding to the CD19 antigen, a protein found on the surface of B-cells, including malignant B-cells in leukemia and lymphoma. This binding triggers an immune response that leads to the destruction of the cancer cells.

Related Terms

  • Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
  • CD19 antigen: A protein found on the surface of B-cells that is often targeted in cancer treatments.
  • B-cells: A type of white blood cell that is vital to the body's immune response.
  • Leukemia: A type of cancer that affects the blood and bone marrow.
  • Lymphoma: A type of cancer that begins in the lymphatic system.

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski